Credit Suisse’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $212M | Sell |
2,888,499
-205,129
| -7% | -$15.8M | 0.2% | 87 |
|
|
2023
Q4 | $251M | Sell |
3,093,628
-394,769
| -11% | -$30.7M | 0.24% | 73 |
|
|
2023
Q3 | $261M | Buy |
3,488,397
+8,325
| +0.2% | +$640K | 0.27% | 68 |
|
|
2023
Q2 | $268M | Sell |
3,480,072
-742
| -0% | -$59.2K | 0.27% | 67 |
|
|
2023
Q1 | $289M | Buy |
3,480,814
+302,683
| +10% | +$25.1M | 0.29% | 60 |
|
|
2022
Q4 | $273M | Sell |
3,178,131
-264,169
| -8% | -$20.9M | 0.29% | 65 |
|
|
2022
Q3 | $212M | Sell |
3,442,300
-98,656
| -3% | -$6.22M | 0.24% | 76 |
|
|
2022
Q2 | $219M | Sell |
3,540,956
-524,654
| -13% | -$32.5M | 0.23% | 72 |
|
|
2022
Q1 | $242M | Buy |
4,065,610
+587,300
| +17% | +$37.5M | 0.21% | 85 |
|
|
2021
Q4 | $253M | Buy |
3,478,310
+56,689
| +2% | +$3.9M | 0.13% | 134 |
|
|
2021
Q3 | $239M | Sell |
3,421,621
-194,149
| -5% | -$13.6M | 0.13% | 144 |
|
|
2021
Q2 | $249M | Buy |
3,615,770
+92,042
| +3% | +$6.15M | 0.13% | 150 |
|
|
2021
Q1 | $228M | Sell |
3,523,728
-321,581
| -8% | -$20.7M | 0.12% | 175 |
|
|
2020
Q4 | $224M | Sell |
3,845,309
-305,747
| -7% | -$18.4M | 0.11% | 189 |
|
|
2020
Q3 | $262M | Sell |
4,151,056
-573,510
| -12% | -$39.8M | 0.16% | 116 |
|
|
2020
Q2 | $364M | Buy |
4,724,566
+1,250,021
| +36% | +$95.8M | 0.26% | 71 |
|
|
2020
Q1 | $260M | Sell |
3,474,545
-284,767
| -8% | -$19.7M | 0.22% | 86 |
|
|
2019
Q4 | $244M | Buy |
3,759,312
+594,677
| +19% | +$38.7M | 0.18% | 100 |
|
|
2019
Q3 | $201M | Buy |
3,164,635
+95,585
| +3% | +$6.25M | 0.17% | 104 |
|
|
2019
Q2 | $207M | Sell |
3,069,050
-25,095
| -0.8% | -$1.65M | 0.18% | 100 |
|
|
2019
Q1 | $201M | Sell |
3,094,145
-578,682
| -16% | -$38.5M | 0.18% | 88 |
|
|
2018
Q4 | $230M | Buy |
3,672,827
+294,732
| +9% | +$20.6M | 0.24% | 70 |
|
|
2018
Q3 | $261M | Buy |
3,378,095
+223,144
| +7% | +$16.9M | 0.23% | 63 |
|
|
2018
Q2 | $223M | Sell |
3,154,951
-877,006
| -22% | -$61.9M | 0.22% | 71 |
|
|
2018
Q1 | $304M | Sell |
4,031,957
-163,181
| -4% | -$13M | 0.28% | 51 |
|
|
2017
Q4 | $301M | Buy |
4,195,138
+102,055
| +2% | +$7.75M | 0.27% | 65 |
|
|
2017
Q3 | $332M | Sell |
4,093,083
-151,235
| -4% | -$11.6M | 0.32% | 50 |
|
|
2017
Q2 | $300M | Sell |
4,244,318
-1,434,257
| -25% | -$95.4M | 0.29% | 59 |
|
|
2017
Q1 | $386M | Sell |
5,678,575
-280,886
| -5% | -$19.8M | 0.35% | 47 |
|
|
2016
Q4 | $427M | Sell |
5,959,461
-966,477
| -14% | -$71.8M | 0.42% | 36 |
|
|
2016
Q3 | $548M | Buy |
6,925,938
+697,289
| +11% | +$56.6M | 0.52% | 25 |
|
|
2016
Q2 | $520M | Buy |
6,228,649
+289,098
| +5% | +$25.7M | 0.58% | 25 |
|
|
2016
Q1 | $546M | Buy |
5,939,551
+674,248
| +13% | +$60.8M | 0.66% | 15 |
|
|
2015
Q4 | $533M | Buy |
5,265,303
+309,984
| +6% | +$32.3M | 0.61% | 16 |
|
|
2015
Q3 | $487M | Sell |
4,955,319
-1,068,229
| -18% | -$119M | 0.58% | 17 |
|
|
2015
Q2 | $705M | Sell |
6,023,548
-841,825
| -12% | -$92M | 0.69% | 14 |
|
|
2015
Q1 | $674M | Sell |
6,865,373
-447,134
| -6% | -$45.4M | 0.68% | 18 |
|
|
2014
Q4 | $689M | Buy |
7,312,507
+800,308
| +12% | +$82.8M | 0.61% | 18 |
|
|
2014
Q3 | $693M | Buy |
6,512,199
+1,458,597
| +29% | +$143M | 0.57% | 20 |
|
|
2014
Q2 | $419M | Sell |
5,053,602
-38,881
| -0.8% | -$3.03M | 0.34% | 39 |
|
|
2014
Q1 | $361M | Sell |
5,092,483
-148,670
| -3% | -$11.7M | 0.35% | 42 |
|
|
2013
Q4 | $394M | Buy |
5,241,153
+522,642
| +11% | +$36.4M | 0.36% | 37 |
|
|
2013
Q3 | $297M | Sell |
4,718,511
-2,122,674
| -31% | -$127M | 0.3% | 51 |
|
|
2013
Q2 | $351M | Buy |
+6,841,185
| New | +$357M | 0.35% | 40 |
|
Other funds holding GILD
Credit Suisse's GILD Position: Q1 2024 in Review
Credit Suisse reduced its Gilead Sciences (GILD) stake by 6.6% in Q1 2024, selling an estimated $15.8M and leaving 2,888,499 shares worth $212M. The position accounts for 0.2% of the portfolio, ranked #87.
Credit Suisse first reported a position in GILD in Q2 2013 and has held it in 44 quarters since. The position peaked at $705M in Q2 2015. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.
- Credit Suisse held 2,888,499 shares of Gilead Sciences worth $212M as of Q1 2024.
- Credit Suisse sold 205,129 Gilead Sciences shares in Q1 2024, an estimated $15.8M.
- Gilead Sciences made up 0.2% of Credit Suisse's portfolio in Q1 2024, its #87 holding.
- Credit Suisse first reported a position in Gilead Sciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Gilead Sciences position peaked at $705M in Q2 2015.
- 1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.